← All trials
NCT04553068
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 15, 2020
- Primary completion
- Apr 22, 2022
- Completion date
- Jun 30, 2022
- First posted
- Sep 17, 2020
- Last posted
- Dec 28, 2020
- Enrollment
- 1730
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Evofem Inc.Lead sponsor
- Evofem Inc.Study director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.